by David Cassak
This past February, on a cold, cloudy day in Beringen, Switzerland, a small town just south of the German border, investment bankers, financial analysts, and investors from all over the...
Jomed's Global Positioning
Over the past several years, Swiss Jomed has been one of the few small European stent companies to grow into a major cardiovascular device company. Last year's successful IPO was testimony to the company's strong sales growth. But it was two deals the company did following soon after the IPO, the acquisitions of US-based MediDyne and EndoSonics, that will test whether Jomed is ready to break out of the pack and compete on a truly global scale with medical device giants such as Guidant and Medtronic.
More from Business Strategy
More from In Vivo
• By
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
• By
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
• By
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.